These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 22123748)

  • 21. The impact of IL2ra induction therapy in kidney transplantation using tacrolimus- and mycophenolate-based immunosuppression.
    Gralla J; Wiseman AC
    Transplantation; 2010 Sep; 90(6):639-44. PubMed ID: 20595929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy.
    Rivinius R; Helmschrott M; Ruhparwar A; Schmack B; Klein B; Erbel C; Gleissner CA; Akhavanpoor M; Frankenstein L; Darche FF; Thomas D; Ehlermann P; Bruckner T; Katus HA; Doesch AO
    Drug Des Devel Ther; 2015; 9():93-102. PubMed ID: 25552900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post-transplant lymphoproliferative disease in kidney transplant patients in the new immunosuppressive era.
    Ciancio G; Siquijor AP; Burke GW; Roth D; Cirocco R; Esquenazi V; Byrne GE; Miller J
    Clin Transplant; 1997 Jun; 11(3):243-9. PubMed ID: 9193850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A retrospective analysis of dermatological lesions in kidney transplant patients.
    Castello M; Gregorini M; Rampino T; Bosio F; Bedino G; Piotti G; Soccio G; Esposito P; Klersy C; Abelli M; Borroni G; Dal Canton A
    Indian J Med Res; 2013 Jun; 137(6):1188-92. PubMed ID: 23852300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Malignancy after renal transplantation in the new era of immunosuppression.
    Watorek E; Boratynska M; Smolska D; Patrzalek D; Klinger M
    Ann Transplant; 2011; 16(2):14-8. PubMed ID: 21716180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Skin cancer after renal transplantation: Results of a multicenter study in Iran.
    Einollahi B; Nemati E; Lessan-Pezeshki M; Simforoosh N; Nourbala MH; Rostami Z; Nafar M; Pourfarziani V; Beiraghdar F; Mahdavi-Mazdeh M; Ahmadpour P; Makhdoomi K; Ghafari A; Ardalan MR; Taebi Khosroshahi H; Oliaei F; Shahidi S; Makhlogh A; Azmandian J; Samimagham HR; Shabazian H
    Ann Transplant; 2010; 15(3):44-50. PubMed ID: 20877266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients.
    Wimmer CD; Angele MK; Schwarz B; Pratschke S; Rentsch M; Khandoga A; Guba M; Jauch KW; Bruns C; Graeb C
    Transpl Int; 2013 Oct; 26(10):999-1006. PubMed ID: 23952102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. De novo malignancies in renal transplant recipients: experience at a single center with 1882 transplant patients over 39 yr.
    Apel H; Walschburger-Zorn K; Häberle L; Wach S; Engehausen DG; Wullich B
    Clin Transplant; 2013; 27(1):E30-6. PubMed ID: 23278453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of immunosuppression for primary renal disease on the risk of cancer in subsequent renal transplantation: a population-based retrospective cohort study.
    Hibberd AD; Trevillian PR; Wlodarczyk JH; Kemp DG; Stein AM; Gillies AH; Heer MK; Sheil AG
    Transplantation; 2013 Jan; 95(1):122-7. PubMed ID: 23238532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of Benefit and Potential Harm of Induction Therapy in Simultaneous Liver-Kidney Transplants.
    AbdulRahim N; Anderson L; Kotla S; Liu H; Ariyamuthu VK; Ghanta M; MacConmara M; Tujios SR; Mufti A; Mohan S; Marrero JA; Vagefi PA; Tanriover B
    Liver Transpl; 2019 Mar; 25(3):411-424. PubMed ID: 30506870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunosuppressive Medications and Squamous Cell Skin Carcinoma: Nested Case-Control Study Within the Skin Cancer after Organ Transplant (SCOT) Cohort.
    Coghill AE; Johnson LG; Berg D; Resler AJ; Leca N; Madeleine MM
    Am J Transplant; 2016 Feb; 16(2):565-73. PubMed ID: 26824445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of induction immunosuppression on patient survival in heart transplant recipients treated with tacrolimus and mycophenolic acid in the current allocation era.
    Amin AA; Araj FG; Ariyamuthu VK; Drazner MH; Ayvaci MUS; Mammen PPA; Mete M; Urey MA; Tanriover B
    Clin Transplant; 2019 Aug; 33(8):e13651. PubMed ID: 31230375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathologic features and outcome of mycophenolate-induced colitis in renal transplant recipients.
    de Andrade LG; Rodrigues MA; Romeiro FG; Garcia PD; Contti MM; de Carvalho MF
    Clin Transplant; 2014 Nov; 28(11):1244-8. PubMed ID: 25142167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Posttransplant lymphoproliferative disorders in kidney transplant recipients: an Iranian multicenter experience.
    Einollahi B; Lessan-Pezeshki M; Nourbala MH; Simforoosh N; Pourfarziani V; Nemati E; Nafar M; Basiri A; Pour-Reza-Gholi F; Firoozan A; Ghadiani MH; Makhdoomi K; Ghafari A; Ahmadpour P; Oliaei F; Ardalan MR; Makhlough A; Samimagham HR; Azmandian J; Razeghi E; Shahbazian H
    Iran J Kidney Dis; 2008 Oct; 2(4):227-33. PubMed ID: 19377242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. De novo noncutaneous malignancies after kidney transplantation are associated with an increased risk of graft failure: results from a time-dependent analysis on 672 patients.
    Cena T; Musetti C; Quaglia M; Magnani C; Stratta P; Bagnardi V; Cantaluppi V
    Transpl Int; 2016 Oct; 29(10):1085-93. PubMed ID: 27343849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer risk with alemtuzumab following kidney transplantation.
    Puttarajappa C; Yabes J; Bei L; Shah N; Bernardo J; McCauley J; Basu A; Tan H; Shapiro R; Unruh M; Wu C
    Clin Transplant; 2013; 27(3):E264-71. PubMed ID: 23480032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three-year follow-up of malignancies in tacrolimus-treated renal recipients--an analysis of European multicentre studies.
    Cowlrick I; Delventhal H; Kaipainen K; Krcmar C; Petan J; Schleibner S
    Clin Transplant; 2008; 22(3):372-7. PubMed ID: 18279418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of mycophenolic acid and tacrolimus on the incidence of infectious complications after kidney transplantation.
    Vnučák M; Graňák K; Skálová P; Laca Ľ; Mokáň M; Dedinská I
    Int Immunopharmacol; 2021 Sep; 98():107908. PubMed ID: 34182244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postrenal transplant malignancy: Incidence, risk factors, and prognosis.
    Elserwy NA; Lotfy EE; Fouda MA; Mahmoud MI; Donia AF; Mashaly ME; Abbas MH; Abuelmagd MM; Abouelenein RK; Ismail MI; Bakr MA
    Saudi J Kidney Dis Transpl; 2017; 28(3):579-588. PubMed ID: 28540896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation.
    O'Neill JO; Edwards LB; Taylor DO
    J Heart Lung Transplant; 2006 Oct; 25(10):1186-91. PubMed ID: 17045930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.